Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$1.32 -23.1%	$1.28	$0.77 ▼ $8.84	$241.78M	0.79	5.83 million shs	18.35 million shs
CRVO CervoMed	$7.11 -8.7%	$9.09	$1.80 ▼ $22.57	$61.88M	-0.23	1.34 million shs	162,328 shs
IMMP Immutep	$1.91 -3.0%	$1.75	$1.32 ▼ $3.05	$278.93M	1.8	218,080 shs	106,718 shs
TRDA Entrada Therapeutics	$7.66 -3.0%	$8.35	$7.10 ▼ $21.79	$290.72M	0.04	132,134 shs	360,715 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	-23.10%	-28.14%	-4.71%	-5.73%	-84.49%
CRVO CervoMed	-8.73%	-16.06%	-21.52%	+217.41%	-64.04%
IMMP Immutep	-3.05%	-1.55%	+11.70%	-1.04%	-31.79%
TRDA Entrada Therapeutics	-3.04%	+2.13%	-16.10%	-35.85%	-50.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGC Canopy Growth	2.1629 of 5 stars	2.5	2.0	2.2	0.0	1.3
CRVO CervoMed	3.2423 of 5 stars	4.4	3.0	2.2	1.7	0.6
IMMP Immutep	1.2564 of 5 stars	3.5	1.0	2.4	0.0	0.0
TRDA Entrada Therapeutics	2.7683 of 5 stars	3.6	2.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	1.00	Sell	$2.00	52.09% Upside
CRVO CervoMed	2.89	Moderate Buy	$27.63	288.54% Upside
IMMP Immutep	3.00	Buy	$7.00	266.49% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	235.07% Upside

Current Analyst Ratings Breakdown

Latest CRVO, TRDA, CGC, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/13/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/12/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/18/2025	CRVO CervoMed	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
3/18/2025	CRVO CervoMed	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $21.00
3/17/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/13/2025	CRVO CervoMed	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
3/13/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00 ➝ $14.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$276.75M	0.87	N/A	N/A	$2.72 per share	0.48
CRVO CervoMed	$7.14M	8.67	N/A	N/A	$1.30 per share	5.47
IMMP Immutep	$5.14M	54.27	N/A	N/A	$1.05 per share	1.82
TRDA Entrada Therapeutics	$172.22M	1.69	N/A	N/A	$7.26 per share	1.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$487.23M	-$3.80	N/A	N/A	N/A	-156.98%	-56.52%	-24.18%	8/7/2025 (Estimated)
CRVO CervoMed	-$2.17M	-$2.18	N/A	N/A	N/A	-118.68%	-44.11%	-39.81%	8/8/2025 (Estimated)
IMMP Immutep	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$0.81	4.82	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)

Latest CRVO, TRDA, CGC, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	N/A
5/12/2025	Q1 2025	CRVO CervoMed	-$0.60	-$0.56	+$0.04	-$0.56	$1.70 million	$1.92 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
3/17/2025	Q4 2024	CRVO CervoMed	-$0.67	-$0.80	-$0.13	-$0.80	$1.51 million	$2.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
IMMP Immutep	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.74	3.52	2.58
CRVO CervoMed	N/A	15.04	15.04
IMMP Immutep	0.01	18.25	18.25
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
CRVO CervoMed	25.15%
IMMP Immutep	2.32%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	1.30%
CRVO CervoMed	35.40%
IMMP Immutep	3.07%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	3,150	183.87 million	153.39 million	Optionable
CRVO CervoMed	4	8.70 million	3.93 million	Not Optionable
IMMP Immutep	2,021	146.04 million	141.09 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

CRVO, TRDA, CGC, and IMMP Headlines

Recent News About These Companies

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29 at 11:28 PM | morningstar.com

Entrada Therapeutics to start DMD trial in Q3 2025

May 29 at 11:28 PM | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29 at 11:28 PM | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28 at 7:00 AM | globenewswire.com

Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

May 24, 2025 | marketbeat.com

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings

May 24, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for TRDA Q2 Earnings?

May 23, 2025 | marketbeat.com

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 23, 2025 | marketbeat.com

Q2 Earnings Forecast for TRDA Issued By HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics' (TRDA) "Buy" Rating Reaffirmed at HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 17, 2025 | marketbeat.com

MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 16, 2025 | marketbeat.com

Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst

May 16, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP

May 16, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12, 2025 | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO, TRDA, CGC, and IMMP Company Descriptions

Canopy Growth NASDAQ:CGC

$1.32 -0.40 (-23.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+0.76%)

As of 05/30/2025 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

CervoMed NASDAQ:CRVO

$7.11 -0.68 (-8.73%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.20 +0.09 (+1.28%)

As of 05/30/2025 07:00 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Immutep NASDAQ:IMMP

$1.91 -0.06 (-3.05%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.92 +0.01 (+0.52%)

As of 05/30/2025 05:27 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Entrada Therapeutics NASDAQ:TRDA

$7.66 -0.24 (-3.04%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.60 -0.06 (-0.78%)

As of 05/30/2025 04:20 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time